PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA fast tracks Merck anticoagulant

The U.S. FDA has granted Fast Track designation for Merck’s investigational anticoagulant therapy MK-2060, giving Merck a push in its quest to provide new standard-of-care treatment for end-stage renal disease (ESRD) patients.

MK-2060 is an investigational monoclonal antibody designed to inhibit Factor XI and its ability to activate downstream proteins involved in the blood coagulation cascade. Merck sees a significant opportunity with the drug candidate for the potential prevention of thrombosis in patients with advanced forms of kidney disease.

“We are encouraged by this Fast Track designation because additional anticoagulation medicines are urgently needed for patients with ESRD who are susceptible to high rates of life-threatening thrombotic events as well as high bleeding risk. Today there is no anticoagulation standard of care for such patients,” said Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

MK-2060 is currently being evaluated in a phase 2 study for the treatment of patients with ESRD receiving hemodialysis. The Fast Track designation makes Merck eligible for more frequent interactions with the FDA and opens the possibility for  Accelerated Approval and Priority Review.

In the ESRD space, Bayer and Ionis are currently partnered on their own Factor XI antisense inhibitor — announcing positive results from a phase 2b trial last month.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026